Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.67 |
| ▸ | IGF1R | P08069 | 1/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamolarizine SCHEMBL1230722 | 0.99 | MEN1 (0.65) | KMT2AMEN1OPRM1OPRD1IGF1R | |
| Tamolarizine SCHEMBL29352586 | 0.99 | MEN1 (0.65) | KMT2AMEN1OPRM1OPRD1IGF1R | |
| Tamolarizine SCHEMBL2194434 | 0.99 | MEN1 (0.65) | KMT2AMEN1OPRM1OPRD1IGF1R | |
| SCHEMBL10985091 | 0.88 | KMT2A (0.67) | KMT2AMEN1OPRM1OPRD1IGF1R | |
| Hydrochloric Acid SCHEMBL10495000 | 0.87 | KMT2A (0.65) | KMT2AMEN1OPRM1OPRD1IGF1R | |
| SCHEMBL10992721 | 0.81 | MEN1 (1.00) | KMT2AMEN1OPRM1OPRD1IGF1R | |
| SCHEMBL7265289 | 0.81 | KMT2A (0.60) | KMT2AMEN1OPRM1OPRD1IGF1R | |
| Hydrochloric Acid SCHEMBL9769781 | 0.80 | ALDH1A1 (0.50) | KMT2AALDH1A1GAATDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL7265661 | 0.80 | KMT2A (0.59) | KMT2AMEN1OPRM1OPRD1IGF1R | |
| SCHEMBL10980359 | 0.80 | MEN1 (0.59) | KMT2AMEN1OPRM1OPRD1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899728-A4 | TREATMENT OF CANCER PATIENTS EXHIBITING ACTIVATION OF THE P-GLYCOPROTEIN EFFLUX PUMP MECHANISM | KANISA PHARMACEUTICALS INC (US) | 2009-03-25 | — | — | EP | claimed |
| EP-1899728-A1 | TREATMENT OF CANCER PATIENTS EXHIBITING ACTIVATION OF THE P-GLYCOPROTEIN EFFLUX PUMP MECHANISM | Kanisa Pharmaceuticals, Inc. (US) | 2008-03-19 | — | — | EP | claimed |
| EP-1898957-A1 | CHEMOTHERAPEUTIC FORMULATIONS OF ZOSUQUIDAR TRIHYDROCHLORIDE AND MODIFIED CYCLODEXTRINS | Kanisa Pharmaceuticals, Inc. (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2007008499-A1 | TREATMENT OF CANCER PATIENTS EXHIBITING ACTIVATION OF THE P-GLYCOPROTEIN EFFLUX PUMP MECHANISM | KANISA PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| WO-2007008496-A1 | CHEMOTHERAPEUTIC FORMULATIONS OF ZOSUQUIDAR TRIHYDROCHLORIDE AND MODIFIED CYCLODEXTRINS | KANISA PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-20070010486-A1 | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins | KANISA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | claimed |
| US-20070009533-A1 | Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism | KANISA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | claimed |
| US-20030220310-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | PHARMACIA CORPORATION | 2003-11-27 | — | — | US | claimed |
| US-20030220312-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| WO-2002009761-A9 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORP (US) | 2003-07-10 | — | — | WO | claimed |
| EP-1303305-A2 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | Pharmacia Corporation (US) | 2003-04-23 | — | — | EP | claimed |
| US-20030073127-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-04-17 | — | — | US | claimed |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | G. D. SEARLE & CO. (US) | 2003-03-20 | — | — | US | claimed |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | SCHUH JOSEPH R (US) | 2002-04-11 | — | — | US | claimed |
| WO-2002009761-A2 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | claimed |
| EP-0256890-B1 | PHARMACEUTICAL COMPOSITION FOR PROTECTION OF BRAIN CELLS | NIPPON CHEMIPHAR CO., LTD. (JP) | 1992-09-02 | — | — | EP | claimed |
| US-4835155-A | Process for protection of brain cells | NIPPON CHEMIPHAR CO., LTD. (JP) | 1989-05-30 | — | — | US | claimed |
| EP-0256890-A2 | Pharmaceutical composition for protection of brain cells | NIPPON CHEMIPHAR CO., LTD. (JP) | 1988-02-24 | — | — | EP | claimed |
| JP-63051328-A | — | — | None | — | — | JP | disclosed |
| US-4528194-A | 2-(4-Diphenylmethylpiperazinyl)-1-phenyl alkanol or their salts, a process for their production and a cerebral circulation-improving drug | NIPPON CHEMIPHAR CO., LTD. (JP) | 1985-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073127-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | CACNB2, CACNA1B, CACNA1F | KMT2A 4575/4885MEN1 3664/4885OPRM1 449/4885 |
| US-20030220312-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders | NR3C2, PTGER4, PTGER1 | KMT2A 4151/4885MEN1 1010/4885OPRM1 521/4885 |
| US-20070009533-A1 | Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism | ABCB1, ABCC5, ABCC1 | KMT2A 1807/4885MEN1 4620/4885OPRM1 2168/4885 |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | PTGER1, KCNN4, HCN1 | KMT2A 3580/4885MEN1 1738/4885OPRM1 309/4885 |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | KCNN4, NR3C2, EDNRA | KMT2A 3555/4885MEN1 1977/4885OPRM1 389/4885 |
| US-20070010486-A1 | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins | CXCR4, CXCR5, CXCR6 | KMT2A 1269/4885MEN1 4182/4885OPRM1 3937/4885 |
| US-20030220310-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | KCNN4, NR3C2, EDNRA | KMT2A 3555/4885MEN1 1977/4885OPRM1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.